Image

Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease

Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease

Recruiting
50-90 years
All
Phase N/A

Powered by AI

Overview

The goal of this study is to investigate whether Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting a part of the brain involved in memory will have an affect on brain activity and whether it may improve memory in people with Mild Cognitive Impairment and Mild Alzheimer's Disease.

The main questions the study seeks to answer are:

  1. Can LIFUP increase brain activity in the targeted area?
  2. Can LIFUP improve memory in people with MCI and mild AD?
  3. Can LIFUP improve connectivity of memory networks in the brain?

Participants in this study will complete MRIs and memory testing, and receive Low Intensity Focused Ultrasound to a part of their brain involved in memory (the entorhinal cortex).

Description

This is a proof of concept trial of Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting the entorhinal cortex in patients with amnestic MCI and Mild Alzheimer's Disease. Participation in the study will entail one Zoom intake session, three in-person sessions and three remote Zoom follow-up sessions over the course of about five weeks. The in-person sessions will take about 5 hours for the first and 3 hours for the following two. The Zoom intake session will take 1-2 hours, and the Zoom follow-up sessions will take about 2 hours each. Participants will be asked to complete questionnaires and tests of learning and memory, have their blood drawn, undergo painless ultrasound stimulation to a part of their brain related to memory, and complete MRI scans of their brain. LIFUP will be administered inside of the MRI scanner, so that we can measure changes in brain activity in real-time.

At the start of the study, you will be randomly assigned to one of four different groups that determines the amount of LIFUP stimulation you will receive. You have an equal chance of being assigned to each group. Participants in one of the three active stimulation groups will receive either 1 dose, 2 doses, or 3 doses of LIFUP at their second in-person session, and will receive the same dose again at their third in-person session. Participants in the placebo group will receive no LIFUP stimulation at either MRI/LIFUP session (in-person visits 2 and 3). However, if at the end of our study, the treatment has been shown to be effective, and you were a placebo subject, we will offer you a free session using the most effective dose.

Eligibility

Inclusion Criteria

  • Amnestic MCI or Mild Alzheimer's diagnosis
  • Age 50-90
  • English-speaking
  • Ability to provide informed consent
  • Normal or corrected-to-normal hearing and vision

Exclusion Criteria

GENERAL

  • Participation in another clinical trial
  • Active use of immunotherapeutic medications for cognition (Aduhelm, Leqembi, Kisunla)
  • Moderate to Severe Alzheimer's
  • Inability to provide informed consent

MRI-Related:

  • Weight exceeding 275 pounds
  • Pregnancy, suspicion of pregnancy, or attempting to become pregnant
  • Claustrophobia
  • Difficulties during previous MRIs
  • Top permanent retainer (bottom only is okay), 5 or more non-removable gold-teeth, metal braces, top spacers, and/or palate expanders
  • Any of the following implants: Cardiac Pacemaker, Aneurysm clips, Cochlear implants, Defibrillator, Electrodes or wires, Magnetically-activated device, Spinal cord stimulator, Infusion or insulin pumps, Implanted drug infusion device, Deep brain stimulation device
  • Non-removable hairpieces, hairpiece extensions, and/or piercings
  • Facial tattoos or permanent makeup
  • Metal implants that are MR-incompatible, or where participant is unable to provide sufficient information to determine MR compatibility
  • Previous injury by metallic foreign body (e.g., bullet, BB, shrapnel) where the object entered the body and participant lacks doctor's confirmation that it was fully removed
    Medical
  • Diagnosis of one or more of the following neurological disorders: Parkinson's disease, Lou Gehrig's disease (ALS), Multiple sclerosis, Cerebral Palsy
  • Diagnosis of one or more of the following genetic disorders: Cystic Fibrosis, Sickle Cell Disease
  • Diagnosis of one or more of the following psychiatric disorders: Bipolar, Psychosis
  • Psychiatric illness that has not been controlled for at least two months (if controlled \>2 months, with or without medication, they are not exclusionary)
  • Severe lung, liver, heart, and/or kidney disease/s (e.g., heart failure, liver failure, and etc...)
  • Diagnosis of thyroid disorder or change of thyroid medication dose within the last 3 months
  • Cancer treatment/s with chemotherapy and/or radiation to head and neck, or stage 4 (metastatic) cancer
  • Autoimmune disorder or viral infection such as HIV, COVID 19, or hepatitis C that has caused current problems with cognition/memory
  • History of substance abuse in the past year
  • History of stroke (Transient ischemic attack / mini-stroke not exclusionary if symptoms lasted \<1 week)
  • History of 2 or more seizures or diagnosis of epilepsy, unless the seizures occurred prior to age 5 alongside a fever.
  • History of brain tumor, brain aneurysm, brain hemorrhage, or subdural hematoma (transient ischemic attack not exclusionary)
  • Head injury that resulted in loss of consciousness lasting \>30 minutes, cognitive issues lasting \>18 months, and/or brain abnormalities visible in CT or MRI scan
  • Uncontrolled high blood pressure or diabetes
  • Heart attack within the last year

Study details
    Mild Cognitive Impairment
    Amnestic Mild Cognitive Disorder
    Deep Brain Stimulation
    Mild Alzheimer's Disease

NCT05417555

University of California, Los Angeles

15 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.